Bruno Lucidi Independent Director Age: 66 Director Since: 2014 Class: II Committee Memberships Audit Compensation Education Saint Romain en Gal, BS Lyon (France), School of Medicine Paris School of Business ( cole Sup rieure de Commerce de Paris) Villejuif Gustave Roussy Institute (France), Oncology New York (USA), Investment Banking Institute Qualifications and Expertise Provided to Our Board Mr. Lucidi has specialized experience in areas critical to our company including an extensive background at Bristol-Myers Squibb, Johnson & Johnson, and GSK commercializing antiviral therapeutics and vaccines on a global scale. Additionally, Mr. Lucidi s leadership roles in building and advancing biopharmaceutical companies, including as Founder and CEO of AgenTus Therapeutics (now Mink Therapeutics) and CEO of Karolinska Development, provides an invaluable perspective to our Board when shaping our business development and commercialization strategies. Professional Experience Life Sciences Expert at the Wallonia Trade and Foreign Investment Government Agency in Belgium (2017-2020) Founder and CEO of AgenTus Therapeutics , a global Cell Therapy company (2017-2019) CEO of Karolinska Development AB , (Nasdaq Stockholm: KDEV) an investment company investing in and managing a portfolio of Nordic life science companies developing potentially ground-breaking treatments for medical conditions where there is an unmet medical need and substantial commercial potential (2014-2015) Vice President of Pediatric Vaccines at GSK Biologicals , responsible for worldwide commercial and life cycle strategy of pediatric vaccines with sales above 2 billion, including vaccines for Hepatitis B, Polio, Rotavirus, Measles, Mumps and Rubella (2009-2012) Worldwide Vice President of Oncology & Virology at Johnson & Johnson , responsible for establishing and managing the virology and the oncology strategic groups, shaping and executing the global strategy from drug discovery to market, overseeing the launch of Velcade, and chairing two therapeutic area committees (2002-2005) CEO of Idenix Pharmaceuticals (1998-2000) and Chair of Pharmasset (1998-2002) with responsibility for overseeing the launch and buildout of these biopharmaceutical companies focused on the development of novel oral antiviral products Leadership roles at Bristol-Myers Squibb , including Senior Director, Virology Europe and Director, Oncology Europe overseeing the launches of Videx (didanosine), Zerit (stavudine) and Taxol (paclitaxel) (1994-1998) Other Public Company Directorships (past five years): None Core Skills Drug Development / Scientific Experience Life Sciences / Healthcare Industry Business Development / Strategic Partnerships Finance & Audit M&A / Strategic Investment Senior Executive Role Corporate Governance